For the interim period of the 2026 fiscal year, net sales were 469 million yen, operating loss was 3,635 million yen, ordinary loss was 3,608 million yen, and net loss attributable to owners of the parent was 3,619 million yen. The full-year forecast was 3,891 million yen in net sales, operating loss of 4,231 million yen, and net loss of 4,331 million yen, with impact from\u672a\u8a08\u4e0a? partnership revenue. Cash and deposits were 977 million yen, and the equity ratio was -44.6%, indicating ongoing over-indebtedness risk. While advancing BCV and IVD development in new businesses, increased R&D expenses continue to weigh on performance. The focus going forward is on fundraising and partnerships.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4582","jir_company_name":"SymBiopharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4582-20260810-01.pdf","jir_short_summary":"For the interim period of the 2026 fiscal year, net sales were 469 million yen, operating loss was 3,635 million yen, ordinary loss was 3,608 million yen, and net loss attributable to owners of the parent was 3,619 million yen. The full-year forecast was 3,891 million yen in net sales, operating loss of 4,231 million yen, and net loss of 4,331 million yen, with impact from\u672a\u8a08\u4e0a? partnership revenue. Cash and deposits were 977 million yen, and the equity ratio was -44.6%, indicating ongoing over-indebtedness risk. While advancing BCV and IVD development in new businesses, increased R&D expenses continue to weigh on performance. The focus going forward is on fundraising and partnerships.","jir_summary":"### Overview of Results\nSymBio Pharmaceuticals recorded for the second quarter of the 2026 fiscal year net sales of 469 million yen, operating loss of 3,635 million yen, ordinary loss of 3,608 million yen, and net loss attributable to owners of the parent of 3,619 million yen for the interim period. Compared with the same period last year, sales declined by 27.3%, with costs increasing, notably a substantial rise in research and development expenses. Cash and deposits at the interim period-end stood at 977 million yen, and the equity ratio was -44.6%, indicating ongoing financial health challenges. The interim full-year forecast remains at net sales of 3,891 million yen, operating loss of 4,231 million yen, and net loss of 4,331 million yen, with impact from unrecorded partnering revenue.\n\n### Future Strategy and Financial Response\nThe company will continue expanding drug development centered on BCV and the IVD business, aiming for new drug approvals and commercialization in the second half of 2028. To secure funding, it is considering equity financing and partnerships with other companies, seeking opportunities to license commercialization rights and co-development. It will work to curb burn rate by renegotiating payment terms and cutting costs, and improve business performance, while maintaining that the timing for resolving over-indebtedness remains uncertain and highlights ongoing concerns about the company as a going concern.","jir_financial_highlights":"Net Sales: 469 (YoY \u25b327.3%)\nOperating loss: 3,635,081 (YoY increased)\nOrdinary loss: 3,608,419 (YoY increased)\nNet income attributable to owners of parent (interim): 3,619,930 (YoY increased)\nEquity ratio: -44.6 (declined vs previous term)\nCash and deposits: 977,184 (unchanged or decreasing tendency)","jir_category":"","jir_hashtags":"#SymBioPharmaceuticals, #FinancialResults, #InterimFinancials","jir_key_figures":"Net sales: 469 \u767e\u4e07\u5186\nOperating loss: \u25b33,635,081 \u5343\u5186\nNet income attributable to owners of parent (interim): \u25b33,619,930 \u5343\u5186","jir_meta_title":"\u3010SymBio Pharmaceuticals\u30112026 Fiscal Year 2Q Financial Summary\uff5cNet sales 469 million yen, net loss widens","jir_meta_description":"Summary of SymBio Pharmaceuticals' interim financial results for the second quarter of the 2026 fiscal year. Details include net sales, losses, cash balance, equity ratio, full-year guidance, and future funding\/partnership strategy.","jir_og_title":"SymBio Pharmaceuticals\uff5c2026 Fiscal Year 2Q Financial Summary","jir_og_description":"Second quarter net sales of 469 million yen, operating loss 3,635 million yen, net loss 3,619 million yen. Attention on over-indebtedness risk and future funding\/partnership trends.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60013,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-101070","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n